Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPEP | Q07075 | 17/20 | 0.62 |
| ▸ | DPP4 | P27487 | 1/20 | 0.49 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.49 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.49 |
| ▸ | BACE1 | P56817 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31151771 | 0.97 | ENPEP (0.60) | ENPEPDPP4DPP8DPP9BACE1 | |
| SCHEMBL29783564 | 0.94 | ENPEP (0.56) | ENPEPBACE1 | |
| SCHEMBL29783567 | 0.94 | ENPEP (0.56) | ENPEPBACE1 | |
| SCHEMBL29400621 | 0.93 | ENPEP (0.54) | ENPEPDPP4DPP8DPP9BACE1 | |
| SCHEMBL29458837 | 0.93 | ENPEP (0.54) | ENPEPDPP4DPP8DPP9BACE1 | |
| SCHEMBL11886063 | 0.93 | ENPEP (0.54) | ENPEPDPP4DPP8DPP9BACE1 | |
| SCHEMBL3708036 | 0.92 | DPP4 (0.56) | ENPEPDPP4DPP8DPP9BACE1 | |
| SCHEMBL3708037 | 0.92 | DPP4 (0.56) | ENPEPDPP4DPP8DPP9BACE1 | |
| SCHEMBL30076058 | 0.91 | ENPEP (0.58) | ENPEPBACE1 | |
| SCHEMBL29788346 | 0.91 | ENPEP (0.74) | ENPEPBACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250206841-A1 | ANTI-TROPHOBLAST CELL SURFACE ANTIGEN 2 (TROP-2) ANTIBODIES | ADEPT BIOPHARMACEUTICAL AND TECHNOLOGY, LTD. (CN) | 2025-06-26 | — | — | US | claimed |
| CN-117858890-A | Polypeptide compound and application thereof in treating enteritis | 四川好医生攀西药业有限责任公司 | 2024-04-09 | — | — | CN | claimed |
| WO-2023192289-A2 | ANTI-TROPHOBLAST CELL SURFACE ANTIGEN 2 (TROP-2) ANTIBODIES | ADEPT THERAPEUTICS INC. (US) | 2023-10-05 | — | — | WO | claimed |
| CN-116621983-A | anti-ROBO 1 humanized antibodies, antigen binding fragments thereof and uses thereof | 四川阿思科力生物科技有限公司 | 2023-08-22 | — | — | CN | claimed |
| CN-116622775-A | Cell for fixed-point knocking in hROBO1CAR, preparation method and application | 四川阿思科力生物科技有限公司 | 2023-08-22 | — | — | CN | claimed |
| US-20220133732-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR CAIX | BICYCLERD LTD (GB) | 2022-05-05 | — | — | US | claimed |
| CN-114409783-A | Anti-human transferrin receptor antibodies across the blood brain barrier | JCR制药股份有限公司 | 2022-04-29 | — | — | CN | claimed |
| EP-4727598-A2 | IMMUNOSORBENT NANOPARTICLES AND METHODS OF USING THEREOF | The Regents of University of California (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20250206841-A1 | ANTI-TROPHOBLAST CELL SURFACE ANTIGEN 2 (TROP-2) ANTIBODIES | ADEPT BIOPHARMACEUTICAL AND TECHNOLOGY, LTD. (CN) | 2025-06-26 | — | — | US | disclosed |
| CN-120199062-A | Traffic organization optimization method and electronic equipment | 杭州海康威视数字技术股份有限公司 | 2025-06-24 | — | — | CN | disclosed |
| US-12239684-B2 | Modulators of complement activity | RA PHARMACEUTICALS, INC. (US) | 2025-03-04 | — | — | US | disclosed |
| US-20250021102-A1 | GENERATING A MISSION PLAN WITH A ROW-BASED WORLD MODEL | FARMX, INC. | 2025-01-16 | — | — | US | disclosed |
| US-20250021101-A1 | ROW-BASED WORLD MODEL FOR PERCEPTIVE NAVIGATION | FARMX, INC. | 2025-01-16 | — | — | US | disclosed |
| US-11331344-B2 | Engineering and delivery of therapeutic compositions of freshly isolated cells | MAXCYTE INC. (US) | 2022-05-17 | — | — | US | disclosed |
| US-20220133732-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR CAIX | BICYCLERD LTD (GB) | 2022-05-05 | — | — | US | disclosed |
| CN-114409783-A | Anti-human transferrin receptor antibodies across the blood brain barrier | JCR制药股份有限公司 | 2022-04-29 | — | — | CN | disclosed |
| EP-3988110-A1 | MODULATORS OF COMPLEMENT ACTIVITY | RA Pharmaceuticals, Inc. (US) | 2022-04-27 | — | — | EP | disclosed |
| EP-3973994-A1 | MODULATION OF COMPLEMENT ACTIVITY | RA Pharmaceuticals, Inc. (US) | 2022-03-30 | — | — | EP | disclosed |
| CN-114028568-A | Method for preventing or treating side effects of tumor therapy | 上海岸阔医药科技有限公司 | 2022-02-11 | — | — | CN | disclosed |
| CN-113975264-A | Method for preventing or treating side effects of tumor therapy | 上海岸阔医药科技有限公司 | 2022-01-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220133732-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR CAIX | CA4, CA2, CA13 | ENPEP 52/4885DPP4 56/4885DPP8 124/4885 |
| US-12239684-B2 | Modulators of complement activity | C3AR1, C1QBP, C5AR1 | ENPEP 93/4885DPP4 452/4885DPP8 469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.